The search to find safe and effective treatment options for PE continues, especially for acute cases, through a number of clinical studies. In a previousblog, we explored how AI-assisted solutions can help manage intermediate-high risk patients. In this post, we summarize a selection of clinical trials that evaluate the efficacy of thrombolytic therapy and medical devices in treating acute PE including intermediate, intermediate-high, and high-risk patients.
Rationale: A previous study (FLARE) showed that percutaneous mechanical thrombectomy using Inari's FlowTriever System was safe and significantly reduced the RV/LV ratio in acute intermediate-risk PE patients.
1 in 20 PE patients is diagnosed with high-risk PE, and they have a 90-day mortality rate of 40%.
Description:The FLAME trial evaluates the treatment outcomes using Inari’s FlowTriever, a mechanical thrombectomy device, in high-risk PE patients.
The FLAME trial is a multicenter, non-randomized, parallel-group, observational study.
Rationale: While there are many treatment options for acute PE, the best treatment option for this condition is still under investigation.
Description: The aim of the HI-PEITHO trial is to compare two acute PE treatment options and address some of the gaps in clinical evidence.
Intermediate-high risk PE patients at a higher risk of early decompensation will either receive ultrasound-facilitated, catheter-directed thrombolysis (low-dose) and anticoagulant, or anticoagulant alone.
HI-PEITHO is a randomized trial with blinded outcome assessment.
Rationale: PEITHO trial showed that while full-dose thrombolytic treatment reduces the risk of hemodynamic instability in intermediate-risk PE patients, it increases the risk of intracranial hemorrhage.
Other studies have shown that reducing the dose of thrombolytic treatment could be effective, while decreasing the risk of bleeding.
Description: PEITHO-3 trial aims to assess the safety and efficacy of a reduced dose of thrombolytic therapy in patients with intermediate-high risk PE.
Patients will receive a reduced dose of Alteplase or placebo. Alteplase will be administered as a 15-minute intravenous infusion at 0.6 mg/Kg (total dose not exceeding 50 mg).
PEITHO-3 is a randomized, double-blind, multicenter, multinational trial with long-term follow-up.
Rationale: EXTRACT-PE trial showed that aspiration thrombectomy using Penumbra’s Indigo aspiration system significantly reduced the RV/LV ratio in symptomatic, submassive acute PE patients. It also reduced the use of thrombolytics.
However, the study focused on short-term outcomes.
Description: The STRIKE-PE trial will evaluate the real world long-term functional outcomes, safety, and performance of Penumbra’s Indigo aspiration system in acute PE patients.
Patients with acute PE and an RV/LV ratio of ≥0.9 will be treated using the Indigo Aspiration System.
STRIKE-PE trial is a single-arm, multicenter trial.
Venous thromboembolism (VTE) can be as challenging to diagnose as it is to treat, and research shows that very few patients have a strong understanding of the condition and its symptoms, often preventing many from seeking care until it is...
Pulmonary embolism (PE) is the third most common cause of cardiovascular death. Hospitals worldwide initiated the movement to assemble multidisciplinary teams or Pulmonary Embolism Response Teams (PERTs) to help manage PE, improve care...